Abstract: The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug for inhibiting ferroptosis.
Type:
Application
Filed:
January 25, 2022
Publication date:
April 11, 2024
Applicants:
Seabelife, Centre National de la Recherche Scientifique (CNRS), Sorbonne Universite, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Claude Bernard Lyon 1, Universite de Rennes 1